Immune-linked MASLD subgroup shows higher risk of liver complications
A team in Japan examined clinical and laboratory data from 349 patients with biopsy-confirmed MASLD and used clustering to sort them into four groups. One group, marked by higher blood IgA, older age, lower platelet counts, and more diabetes, had the greatest burden of advanced fibrosis and the highest rate of later liver-related events. Additional tissue and single-cell analyses detected IgA-producing B-lineage cells in portal areas of the liver, pointing to immune interactions along the gut-liver axis.
The Japanese study drew on 349 biopsy-confirmed MASLD cases. Unsupervised clustering produced four patient groups. Cluster 2 combined elevated blood IgA with older age, lower platelets, and more diabetes, and showed the greatest advanced fibrosis burden. Over a median 6.8 years, 20 liver-related events occurred; this cluster's five-year cumulative incidence was 24.0%. An IgA level at or above 318 mg/dL independently forecast such events after fibrosis was considered.
Findings recurred in a 287-patient biopsy-free cohort and a 272-patient multicenter cohort. Tissue work linked IgA to intestinal barrier dysfunction and found IgA-producing B-lineage/plasma cells in portal liver areas, with higher IGHA1 expression in advanced fibrosis.
For patients with MASLD, an IgA-based subgroup could eventually help clinicians identify those needing closer monitoring, though it is not yet a routine test. Families and health systems may face different follow-up needs if such immune markers are validated. Because the findings come from specific cohorts, broader screening or treatment changes would require further study; the work may mainly shape research priorities and conversations about risk beyond fibrosis.